Neurodegenerative Diseases Market Global Research and Clinical Survey 2019 to 2025

Neurodegenerative Diseases market report involves an in-depth understanding of Neurodegenerative Diseases market and highly delivers market insights based on market intelligence studies. Adhering to industry norms, the report comprises chapter wise factual information spread across 100+ pages. Also, prepared by a panel of seasoned analysts, it offers the client with insightful data that establishes the base to take immediate steps ahead. Nonetheless, Neurodegenerative Diseases market offers growth opportunities in the near future exhibited in best information format through this report.

Get a sample copy before purchase:

Companies Covered (Revenue and Market Share)-

Novartis, Merck Serono, Teva Pharmaceutical, UCB, Pfizer, Biogen Idec, Bayer Schering Pharma AG, Boehringer Ingelheim, Addex Pharmaceutical, Amarin, AstraZeneca, Asubio Pharmaceutical, Bial, Alector, Yumanity Therapeutics, Eisai, H.Lundbeck A/S, Jiangsu Hansoh Pharmaceutical, Yangtze River Pharmaceutical Group, Chongqing Zein Pharmaceutical, Among others.

The leading players of Neurodegenerative Diseases industry, their market share, product portfolio, company profiles are covered in this report. The competitive market scenario among Neurodegenerative Diseases players will help the industry aspirants in planning their strategies.

Scope Of the report:

As per the scope of this report, neurodegenerative disease is a broad term used to denote a range of conditions that primarily affect the neurons in the brain. Neurodegenerative diseases are incurable, and the degradation of neurons leads to the gradual death of neurons. The market is segmented by indication type, drug type, and geography.

Key Market Trends

Parkinson’s Disease Segment by Indication Type is Expected to Be the Fastest Growing Segment

The initial symptoms of Parkinson’s disease include shaking, rigidity, uneasiness in walking, and slowness. Anxiety and depression are very common in patients suffering from Parkinson’s disease. Anti-Parkinson drugs, such as Levodopa and Carbidopa, are the most commonly administered drugs, along with dopamine agonists. Ropinirole, Pramipexole, and Rotigotine are some common dopamine agonists prescribed for the disease.

Selegiline and Rasagiline are the drugs that conserve dopamine and prevent degradation. COMT inhibitors are also administered to prevent the degradation of dopamine. According to the Parkinson’s Disease Foundation, nearly 10 million people worldwide are living with Parkinson’s disease. The risk of Parkinson’s disease increases with age. The growing aging population, especially in North America and Europe, is the primary factor propelling the growth of the market.

The increasing awareness and incidences of the disease are boosting the market growth. According to the Parkinson’s Disease Foundation, medication cost for a patient with the disease is on an average USD 2,500 a year, and therapeutic surgery costs nearly USD 100,000 per person. In 2017, North America accounted for the largest market, followed by Europe and Asia-Pacific.

Available discount (Upto 30%)@

North America is Expected to Dominate the Market

North America is the most significant region in the Parkinson’s drugs market. As many as one million Americans live with Parkinson’s disease (PD), which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy, and Lou Gehrig’s disease. According to Parkinson’s news, 2018, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by 2030.

It is the second-most common neurodegenerative disorder in the United States. Also, there are thousands of patients who go undetected. As the US population continues to age, the number of people living with Parkinson disease (PD) continues to grow, and it is expected to double between 2010 and 2040.

Geographically, the report takes stock of the potential of Neurodegenerative Diseases market in the regions of North America including the U.S. and Canada, Latin America including Mexico, Brazil, and Argentina, Europe including the U.K., Germany, France, Italy, Spain, and Nordic, Asia Pacific except Japan (APEJ) including India, China, Thailand, Malaysia, Singapore, and Australia, and the Middle East and Africa including Gulf Cooperation Council (GCC), South Africa, Israel, and Nigeria.

Table of Contents:

1 Report Overview

2 Executive Summary

3 Key Players

4 Breakdown Data by Type and Application

5 North America

6 Europe

7 China

8 Japan

9 International Players Profiles

10 Market Dynamics

11 Key Findings in This Report

12 Appendix

The competitive spectrum of the Neurodegenerative Diseases market has been dealt with firmly in the report. The vast expanse of this information is certain to help potential stakeholders and plausible new entrants gain an insight about the Neurodegenerative Diseases market and the various challenges it presents. The details about the competitive landscape presented in the report may also provide an evaluation of the prominent market vendors, their growth profiles, growth strategies, etc., helping stakeholders in quicker decision-making.

For complete report description click here:

Reasons to Purchase This Report:

  • Current and future Neurodegenerative Diseases market outlook in the developed and emerging markets.
  • Porters five forces analysis
  • Regional Analysis
  • Latest developments and strategies employed by the major market players.
  • Post sales analyst support, along with the Market Estimate sheet (in excel).
  • Custom Reports: This report can be customized to meet your requirements.

Note: Please connect with our representative, who will ensure you to get a report that suits your needs.

Contact Us:

Irfan Tamboli (Sales)

Phone: + 1704 266 3234 | +91-750-707-8687 |


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button